KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit-MedSci.cn

KEYNOTE-042 rolls back programmed cell death ligand 1 threshold for non-small cell lung cancer pembrolizumab monotherapy without new insight into those deriving benefit

Cummings, AL; Garon, EB

Garon, EB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Hematol Oncol, 2825 Santa Monica Blvd,Suite 220, Los Angeles, CA 90404 USA.

TRANSLATIONAL LUNG CANCER RESEARCH, 2019; 8 (): S403

科室
- - 订阅+
  - 更多科室
工具
服务